The Cell-Free Shift: EVerZom Clears Preclinical Hurdle for Crohn's Therapy

STRASBOURG, France – September 30, 2026 – In the high-stakes arena of regenerative medicine, the transition from live cell therapies to cell-free alternatives is rapidly moving from theoretical white papers to tangible clinical assets. EVerZom, a French biotechnology company specializing in exosome-based therapies, has officially completed the CTA-enabling preclinical safety and biodistribution studies for its lead drug candidate, EVerGel.

These nonclinical results validate a favorable safety profile across two animal species, clearing the runway for the company to submit its Clinical Trial Application (CTA). With regulatory discussions now in the crosshairs, the Strasbourg-based firm aims to achieve first-in-human administration by the end of the first half of 2027.

The milestone is more than just a regulatory checkbox; it represents a strategic pivot in how the biotechnology sector is addressing complex perianal fistulas associated with Crohn’s disease—a debilitating condition where conventional biologics and surgical interventions frequently fall short.

The Cell-Free Evolution: Eclipsing Live Stem Cells

To understand the market significance of EVerZom’s latest milestone, one must look at the recent history of cell therapies in gastroenterology. For years, live mesenchymal stem cells (MSCs) were heralded as the ultimate solution for tissue repair. However, the commercial and clinical reality proved far more complex. The European withdrawal of Alofisel (darvadstrocel)—a live MSC therapy—in December 2024, following its failure to demonstrate superior efficacy over a placebo in the ADMIRE-CD II trial, left a massive therapeutic void.

Live cell therapies are notoriously difficult to manage. They present logistical nightmares regarding cold-chain transport, suffer from inconsistent efficacy due to poor cell survival post-injection, and carry high manufacturing costs.

Enter exosomes: the extracellular vesicles secreted by cells that carry proteins, lipids, and nucleic acids. By harvesting the exosomes derived from MSCs rather than using the live cells themselves, developers can theoretically bypass the logistical bottlenecks of live cell therapies. Exosomes offer superior shelf-stability, reduced immunogenicity, and the tantalizing promise of true "off-the-shelf" availability.

“The successful completion of these CTA-enabling preclinical studies represents a pivotal milestone for the company’s entire pipeline,” said Jeanne Volatron, Co-Founder and CEO of EVerZom. “The results validate not only the safety of EVerGel but also the relevance of our technology platform. We are now fully focused on preparing for clinical development, with the ambition of rapidly bringing a solution to patients living with severe conditions.”

Closing the Fistula: A Novel Regenerative Approach

Complex perianal fistulas severely impair the quality of life for Crohn’s patients. Current medical management typically involves antibiotics to control infection, followed by immunomodulators and biologics like infliximab or newer JAK inhibitors to manage underlying inflammation. Yet, even with aggressive biologic therapy, structural healing of the fistula tract is rarely achieved. Surgical interventions, such as advancement flaps or the Ligation of Intersphincteric Fistula Tract (LIFT) procedure, are frequently deployed but are plagued by high recurrence rates.

EVerZom’s approach with EVerGel attempts to solve a critical mechanical and biological problem: keeping the therapeutic agent at the site of the injury long enough to promote tissue healing. Exosomes, if injected alone as a liquid suspension, are rapidly cleared by the body's lymphatic system.

To counter this, EVerZom engineered a proprietary formulation that embeds MSC-derived exosomes within a biocompatible, thermoresponsive hydrogel. Liquid at room temperature, the hydrogel solidifies upon injection into the body. This creates an occlusive plug within the fistula tract, physically sealing the lesion while serving as a local reservoir for the sustained release of regenerative exosomes.

“Complex perianal fistulas associated with Crohn’s disease remain difficult to manage. These nonclinical studies are a preliminary step toward evaluating EVerGel in patients,” noted Prof. Damián García-Olmo, MD, PhD, Head of the Department of Surgery at Fundación Jiménez Díaz University Hospital in Madrid. “Clinical studies will be needed to assess its safety and explore its therapeutic potential in this indication.”

Navigating the Regulatory and Manufacturing Labyrinth

While the scientific rationale for exosome therapy is robust, the regulatory landscape remains a complex frontier. Both the European Medicines Agency (EMA) and the FDA are still actively shaping the frameworks that govern these novel modalities.

Because EVerGel combines a biological product (exosomes) with a medical device component (the hydrogel), it navigates the regulatory pathway as a combination product. Fulfilling the rigorous biodistribution and toxicity requirements across two animal species essentially de-risks the upcoming CTA submission. It proves to regulators that the exosome-hydrogel matrix does not migrate dangerously through the body or trigger systemic toxicity.

Equally critical to EVerZom's long-term viability is its manufacturing capability. The Achilles' heel of the broader exosome industry has been scalability. Traditional production methods yield notoriously low quantities of extracellular vesicles, driving up the Cost of Goods Sold (COGS) to commercially unviable levels.

EVerZom has built a proprietary bioproduction platform designed to shatter this bottleneck. By exerting controlled mechanical stimulation on cells cultured in 3D turbulent flow bioreactors, the company forces the cells to release vesicles at a dramatically accelerated rate. Industry analysts note that this mechanical stress approach can boost yields up to 100 times higher than conventional static cultures. Recently, the company validated this approach by achieving the first bioproduction of clinical-grade stem cell-derived exosomes in large-scale bioreactors in partnership with the French Blood Establishment (EFS).

Translational Velocity and Market Strategy

From a corporate strategy perspective, EVerZom provides a compelling case study in "translational velocity"—the speed and efficiency with which a biotech firm moves a discovery from the academic laboratory to human trials. Founded in 2019 out of research from the Matière et Systèmes Complexes laboratory (Université Paris Cité & CNRS), the company has systematically dismantled the barriers to clinical entry.

Financial readiness is a core pillar of this velocity. In October 2025, EVerZom closed a €10 million financing round backed by a syndicate of public and private investors, including the EIC Fund, Capital Grand Est, Sorbonne Venture by Audacia, and Aloe Private Equity. This was bolstered by an additional €3 million grant from Bpifrance under the France 2030 initiative, specifically earmarked for scaling their GMP-compliant bioproduction to 50-liter bioreactors.

This blended finance model—leveraging both venture capital and sovereign wealth designed to retain advanced manufacturing capabilities within Europe—provides EVerZom with a robust financial runway. The capital structure is explicitly designed to carry the company through the completion of its Phase 1 clinical trials.

As the biotechnology sector increasingly demands platforms rather than single-asset wonders, EVerZom is already positioning its technology for broader applications. While EVerGel targets Crohn’s fistulas, the company is concurrently advancing preclinical programs in hepatology—such as Eviv for acute-on-chronic liver failure—and exploring applications in ophthalmology.

The successful completion of these CTA-enabling studies marks the end of EVerZom's purely preclinical chapter. As the company finalizes its regulatory dossiers and prepares for its 2027 clinical debut, the broader market will be watching closely to see if this cell-free, hydrogel-retained approach can finally deliver a durable solution to one of gastroenterology's most intractable challenges.